A phase II trial of JDQ443 in - ASCO Publications
2023年5月31日 · JDQ443 is a potent, selective KRAS G12C inhibitor that irreversibly traps KRAS G12C in its inactive, GDP bound state and blocks downstream signaling. In preliminary data from the Phase Ib part of the KontRASt-01 study (NCT04699188), JDQ443 showed promising antitumor activity and an acceptable safety profile in previously treated pts with KRAS ...
KontRASt-01 update: Safety and efficacy of JDQ443 in
2023年5月31日 · JDQ443 is a selective, covalent, orally bioavailable KRAS G12C inhibitor that irreversibly traps KRAS G12C in the inactive, GDP-bound state. Clinical activity was seen in initial cohorts of patients (pts) treated with JDQ443 monotherapy, and 200 mg twice daily (BID) was selected as the recommended dose (RD) for expansion (Tan DS, et al .
KontRASt-02: A phase III trial investigating the efficacy and safety …
2023年5月31日 · JDQ443 is a potent, structurally novel, selective KRAS G12C inhibitor that irreversibly traps KRAS G12C in its inactive, GDP-bound form. Data from the JDQ443 monotherapy arm of the first-in-human KontRASt-01 study demonstrated encouraging anti-tumor activity and an acceptable safety profile of JDQ443 in pts with previously treated, KRAS G12C ...
free survival (IPFS) per mRANO-BM. Concentration and PK parameters of JDQ443, TNO155, and / or tislelizumab. including changes in laboratory values, electrocardiograms, and vital signs. Frequency of dose interruptions, reductions, and dose intensity by treatment. Better treatments are needed for patients harboring the KRAS G12C mutation.
A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC
2024年1月1日 · JDQ443 is a potent, selective KRAS G12C inhibitor that irreversibly traps KRAS G12C in its inactive, GDP bound state and blocks downstream signaling. In preliminary data from the Phase Ib part of the KontRASt-01 study (NCT04699188), JDQ443 showed promising antitumor activity and an acceptable safety profile in previously treated pts with KRAS ...
KontRASt-02: A Phase III Trial Investigating the ... - ScienceDirect
2024年1月1日 · JDQ443 is a potent, structurally novel, selective KRAS G12C inhibitor that irreversibly traps KRAS G12C in its inactive, GDP-bound form. Data from the JDQ443 monotherapy arm of the first-in-human KontRASt-01 study demonstrated encouraging antitumor activity and an acceptable safety profile of JDQ443 in pts with previously treated, KRAS G12C ...
200 mg oral JDQ443 twice daily continuously or 75 mg/m2 intravenous docetaxel once every 21 days. The primary endpoint of this study is pro-gression-free survival (PFS) per Blinded Independent Review Committee (BIRC) according to RECIST version 1.1. The key secondary endpoint is overall survival (OS); other secondary endpoints include objective ...
The current study aims to assess the effect of comorbidity on survival fol-lowing SBRT for high-risk early-stage NSCLC patients. Materials/Methods: We retrospectively reviewed 63 patients with early-stage NSCLC, ≥4 cm (T2-T3, N0), treated with SBRT, between September 2013 and May 2022 at a single institution. SBRT is defined as five fractions
A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD …
2024年1月1日 · JDQ443 is a potent, selective KRAS G12C inhibitor that irreversibly traps KRAS G12C in its inactive, GDP bound state and blocks downstream signaling. In preliminary data from the Phase Ib part of the KontRASt-01 study (NCT04699188), JDQ443 showed promising antitumor activity and an acceptable safety profile in previously treated pts with KRAS ...
2024年4月9日 · CCTG IND.242 is a neoadjuvant platform trial for molecularly defined non-small cell lung cancer. The IND.242A Substudy enrolls a maximum of 27 patients and evaluates major pathological response rate after neoadju-vant JDQ443 (opnurasib), a …